
Natalizumab extended interval dosing (EID) is associated with a significant reduction in progressive multifocal leukoencephalopathy (PML) risk compared with standard interval dosing (SID) in the TOUCH® Prescribing Program
Zhovtis, Ryerson Lana, Foley, John, Chang, Ih, Kister, Ilya, Cutter, Gary, Metzger, Ryan, Goldberg, Judith D., Li, Xiaochun, Riddle, Evan, Smirnakis, Karen, Yu, Bei, Ren, Zheng, Hotermans, Christophe,Volume:
175
Langue:
english
Journal:
Revue Neurologique
DOI:
10.1016/j.neurol.2019.01.272
Date:
April, 2019
Fichier:
PDF, 107 KB
english, 2019